REG - Nuformix PLC - NXP002 Completion of Tolerability Studies

NuformixAnnouncement

10/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220810:nRSJ4681Va&default-theme=true

RNS Number : 4681V  Nuformix PLC  10 August 2022

10 August 2022

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

 

NXP002 Successful Completion of Tolerability Studies

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce that NXP002, a new form of tranilast and a potential novel inhaled
treatment for Idiopathic Pulmonary Fibrosis ("IPF"), has successfully
completed pre-clinical tolerability studies for a new NXP002 formulation.

 

As announced on 27 June 2022, the Company initiated further pre-clinical
studies as it continues to generate a robust data package to support the
progression of NXP002. Tolerability has been demonstrated across a new range
of doses, including higher doses than previously given, delivered using an
alternative method designed to ensure that consistent and controlled
inhalation exposure is achieved.

 

Work has now commenced to explore how the new doses studied can best optimise
efficacy and confirm NXP002's positive pharmacological profile towards the
treatment of lung fibrosis and inflammation via inhalation, before progression
to a final step to assess duration of action. Results will continue to be
generated throughout H2 2022 and further updates will be announced in due
course.

 

Dr Daniel Gooding, Executive Director of Nuformix, commented: "The results
from this first stage are exactly what we had hoped for and bode well for the
inhaled tolerability of NXP002, even at high doses. We are pleased that we can
now progress to robustly investigate NXP002's efficacy as we continue to build
a pre-clinical data package to support the further progression of the
Company's lead programme.  I look forward to providing further updates to the
market when appropriate."

 

Enquiries:

 

 Nuformix plc
 Dr Daniel Gooding, Executive Director             Via IFC Advisory

 Dr Julian Gilbert, Non-executive Chairman

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

About Fibrosis

Fibrotic disease is typically associated with high patient mortality,
increasing prevalence and a lack of safe and effective treatments. Whilst
fibrosis treatments are in their infancy the emerging lung fibrosis market
demonstrates their blockbuster potential. Idiopathic Pulmonary Fibrosis is
classified as a rare disease and presents a global commercial market that is
forecast to grow to $5bn by 2025. Sales of standard-of-care therapies OFEV and
Esbriet achieved $2.58bn and $1.04bn respectively in 2021.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSSIFMUEESEDA